# A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

> **NCT07028073** · PHASE1,PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 78 (estimated)

## Conditions studied

- Acute Myeloid Leukemia With T(8;21)(Q22;Q22)
- Acute Myeloid Leukemia With T(16;16)(P13;Q22)
- KIT Gene Mutation
- Avapritinib

## Interventions

- **DRUG:** Group A (FIT): Avapritinib + IA regimen
- **DRUG:** Group B (UNFIT): Avapritinib + VA regimen

## Key facts

- **NCT ID:** NCT07028073
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2027-05-15
- **Final completion:** 2027-12-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028073, "A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07028073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*